Summary
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 15,809 | $261,800 | $278,080.31 | $16,280.31 | 6.22% |
 Daniel Loeb | 85,000 | $1.41M | $1.45M | $41,649.91 | 2.96% |
| AF Anthony Fasano Clark Estates INC/NY | 881,000 | $13.2M | $14.77M | $1.57M | 11.88% |
 Larry Robbins Glenview Capital Management | 1.92M | $26.88M | $33.74M | $6.86M | 25.54% |
 Anthony Scaramucci SkyBridge Capital II LLC | 53,000 | $877,680 | $930,150 | $52,470 | 5.98% |
Bausch + Lomb Corporation (BLCO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bausch + Lomb Corporation ever had a stock split?
Bausch + Lomb Corporation Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Brenton L. Saunders CEO | NYSE Exchange | 071705107 CUSIP |
| CA Country | 13,000 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Bausch + Lomb Corporation is a globally recognized eye health company with operations spanning several key markets, including the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and beyond. The company is structured into three main segments: Vision Care, Pharmaceuticals, and Surgical, each catering to different aspects of eye health and treatment needs. Founded in 1853, Bausch + Lomb has established its headquarters in Vaughan, Canada, demonstrating a long-standing commitment to providing innovative eye health solutions. Operating as a subsidiary of Bausch Health Companies Inc., Bausch + Lomb utilizes both direct sales forces and independent distributors to sell its wide array of products and services across the globe.
Products and Services
- Vision Care
This segment offers a broad spectrum of contact lenses catering to various wearing modalities, including daily disposable and frequently replaced options. Bausch + Lomb also provides a range of contact lens care products, which includes over-the-counter eye drops, eye vitamins, and mineral supplements targeting conditions like eye allergies, conjunctivitis, dry eye, and redness relief.
- Pharmaceuticals
In the Pharmaceuticals segment, Bausch + Lomb offers both proprietary and generic pharmaceutical products designed for post-operative treatments, as well as for managing glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. This segment leverages innovative research to develop treatments that address some of the most pressing eye health issues faced by patients worldwide.
- Surgical
This segment focuses on providing medical device equipment, consumables, and technologies needed for treating a variety of eye conditions including cataracts, corneal, vitreous, and retinal issues. Bausch + Lomb offers intraocular lenses and delivery systems, phacoemulsification equipment, and other essential surgical instruments and devices needed for cataract surgery. This demonstrates the company’s commitment to supporting eye surgeons with the tools and technologies needed for effective treatment procedures.
